Alpha-1-antitrypsin deficiency: heterozygosity, intermediate levels, and pulmonary disease
- PMID: 5575669
- DOI: 10.1378/chest.59.5_supplement.16s
Alpha-1-antitrypsin deficiency: heterozygosity, intermediate levels, and pulmonary disease
Similar articles
-
The prevalence of alpha 1-antitrypsin deficiency in selected groups of patients with chronic obstructive lung disease.Mayo Clin Proc. 1969 Oct;44(10):697-710. Mayo Clin Proc. 1969. PMID: 5344805 No abstract available.
-
[Alpha-1-antitrypsin deficiency associated with chronic bronchopneumopathy and essential emphysema].Poumon Coeur. 1967;23(9):1119-30. Poumon Coeur. 1967. PMID: 4176461 French. No abstract available.
-
Antitrypsin deficiency in pulmonary disease: the significance of intermediate levels.Ann Intern Med. 1969 Sep;71(3):533-42. doi: 10.7326/0003-4819-71-3-533. Ann Intern Med. 1969. PMID: 5809680 No abstract available.
-
Precocious emphysema and alpha 1 antitrypsin deficiency.Adv Intern Med. 1971;17:379-92. Adv Intern Med. 1971. PMID: 4949908 Review. No abstract available.
-
[Editorial: The Pi system and alpha-1-antitrypsin deficiency states].Nouv Presse Med. 1973 Oct 1;2(36):2375-7. Nouv Presse Med. 1973. PMID: 4594170 Review. French. No abstract available.
Cited by
-
Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.Respir Res. 2005 Jan 31;6(1):12. doi: 10.1186/1465-9921-6-12. Respir Res. 2005. PMID: 15683545 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources